SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...

Work in the fruitfly now provides details of one such transition, which involves interactions of the Notch pathway with both cell-cycle regulators and Hedgehog (HH) signalling components.

Myriad Genetics is a leading molecular diagnostic ... including statements relating to the transition of senior leadership at the Company, accelerating the Company’s strategy to drive continued ...

Myriad Genetics is a leading molecular diagnostic testing and precision ... including statements relating to the transition of senior leadership at the Company, accelerating the Company's strategy to ...